---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-026588"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2022-10-19T23:59:59+00:00"
generated_at: "2026-06-23T02:43:56.498934+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance

## Summary
- Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.
- Raises FY2022 adjusted EPS guidance to $5.17-$5.23; GAAP guidance $3.75-$3.81.
- U.S. Medical Devices sales +11.3%; FreeStyle Libre revenues ~$1.0B in Q3.
- COVID testing-related sales $1.7B in Q3 vs $1.9B a year ago; full-year outlook $7.8B.
- Restarted infant formula production at Sturgis plant; quarterly dividend $0.47/share payable Nov. 15.

## SEC filing metadata
- accession: 0001628280-22-026588
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2022-10-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828022026588/0001628280-22-026588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828022026588/abt-20221019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-026588
- JSON: https://secwatch.observer/filing/0001628280-22-026588.json
- Plain text: https://secwatch.observer/filing/0001628280-22-026588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.